Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price & How to Invest
Last updated November 2026
Short answer
Alnylam (ALNY) is a large-cap, commercial-stage biotech that pioneered RNA interference (RNAi) therapeutics, and its investment case rests on a single fast-growing franchise: Amvuttra for TTR amyloidosis. You can invest by buying ALNY on the Nasdaq like any stock, or hold it inside a diversified basket alongside other biotech or healthcare names. It crossed into sustained profitability in 2025, but a July 2026 cut to its TTR sales guidance sent the shares down sharply: as of October 16, 2026 they closed near $236, down about 41% year to date, for a market cap of roughly $31.5 billion.
ALNY stock price
As of 2026-11-16, Alnylam Pharmaceuticals, Inc. (ALNY) last closed at $159.73, down 65.3% over the past year. Over the past 52 weeks it has traded between $151.64 and $473.29.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Alnylam Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
ALNY key stats
At $159.73 on November 16, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) has a market cap of $21.4B and a P/E of 8.1 on trailing earnings (14.7 on forward earnings).
- Market cap
- $21.4B
- P/E (trailing)
- 8.1
- P/E (forward)
- 14.7
- EPS (trailing 12 months)
- $19.80
- Price to book
- 5.9
- Beta
- 0.44
Market cap, P/E and yield are measured at the $159.73 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Alnylam Pharmaceuticals, Inc. (ALNY)?
The last two weeks for Alnylam Pharmaceuticals, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ALNY closed at $159.73 on November 16, 2026, up 2.0% over the past five trading days (from $156.61).
- On November 5, 2026, Alnylam Pharmaceuticals, Inc. filed an 8-K with the SEC reporting a change in its directors or officers and other events (Item 5.02, Item 8.01). Read the 8-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Alnylam Pharmaceuticals, Inc. (ALNY) do?
Alnylam Pharmaceuticals is the company that turned RNA interference, a Nobel-winning biological mechanism for silencing disease-causing genes, into an approved class of medicines. Its commercial portfolio includes Amvuttra (vutrisiran) and Onpattro for transthyretin (TTR) amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for a rare kidney disorder, plus royalties on Leqvio, an cholesterol-lowering RNAi drug marketed by partner Novartis. The defining event was the March 2025 FDA approval of Amvuttra for ATTR amyloidosis with cardiomyopathy (ATTR-CM), a far larger patient population than its earlier polyneuropathy indication, based on the HELIOS-B trial showing a 28% reduction in death and cardiac events.
That label expansion transformed the financial profile. Full-year 2025 net product revenue reached roughly $3 billion, up about 81%, and total revenue including royalties and collaborations was about $3.7 billion, with GAAP and non-GAAP profitability for the first time. Growth continued into 2026: Q2 net product revenue rose 74% to about $1.17 billion, with Amvuttra alone at about $1.01 billion, up 106%, and trailing twelve-month total revenue reached about $4.8 billion with net income near $775 million. The surprise came with that July 30, 2026 report. Management cut 2026 TTR guidance to $4.2 billion to $4.5 billion (from $4.4 billion to $4.7 billion) and total net product revenue guidance to $4.7 billion to $5.1 billion (from $4.9 billion to $5.3 billion), saying second-line US demand for Amvuttra had normalized after an early burst of pent-up demand from patients waiting on stabilizers. Q2 EPS of about $1.84 also missed the roughly $2.14 consensus. The shares fell about 28% in a day to a 52-week low of $197.81, and on October 16, 2026 they closed near $236, down about 41% year to date and about 51% over one year from a 52-week high of $495.55. The investment picture is now less about whether the science works or whether the company can make money, and more about how durably Amvuttra can grow the ATTR-CM market against oral competitors, plus what its earlier-stage pipeline (Alzheimer's, bleeding disorders) can add on top.
What's driving Alnylam Pharmaceuticals, Inc. (ALNY)?
1. Amvuttra ATTR-CM ramp
The March 2025 approval of Amvuttra for ATTR cardiomyopathy opened a market many multiples larger than its original polyneuropathy indication, and the launch remains the single biggest growth driver: Amvuttra revenue rose 106% to about $1.01 billion in Q2 2026. As a subcutaneous injection dosed once every three months, it offers a convenience angle versus daily oral therapies. The July 2026 guidance cut, to $4.2 billion to $4.5 billion of TTR revenue, came because second-line demand normalized after the initial wave of switching patients, so first-line uptake is now the number to watch. Alnylam reports Q3 results on October 29, 2026, with consensus near $1.43 billion of revenue and $2.26 EPS.
2. Crossing into sustained profitability
After years of heavy R&D spending, Alnylam reached GAAP and non-GAAP profitability in 2025 and has kept it: net income was about $206 million in Q1 2026 and about $164 million in Q2, and non-GAAP operating income reached about $318 million in Q2, up from about $95 million a year earlier. Trailing net income is near $775 million on an operating margin around 18%. Cash and marketable securities rose to about $3.3 billion at June 30, 2026, so the commercial engine now funds the pipeline and reduces the historical risk of dilutive capital raises.
3. RNAi platform and pipeline optionality
Beyond TTR, Alnylam is advancing mivelsiran in Alzheimer's disease, ALN-6400 in a bleeding disorder, and other programs with data readouts expected across the year. Its RNAi delivery technology has already produced multiple approved drugs, giving the platform repeatability that early-stage biotechs lack. Novartis royalties on Leqvio add a growing, lower-risk revenue stream tied to the large cardiovascular market.
4. Global label and geographic expansion
The ATTR-CM indication has secured approvals beyond the US, including the European Commission, Japan, the UK, Brazil, and Canada. Each new geography adds addressable patients to the same commercial franchise without requiring a new drug. This international runway supports the multi-year growth trajectory embedded in analyst expectations.
What are the risks to Alnylam Pharmaceuticals, Inc. (ALNY)?
Revenue is heavily concentrated in the TTR franchise, and the July 2026 guidance cut showed how sensitive the stock is to even a modest change in Amvuttra's trajectory: a roughly 4% trim to the total revenue range produced a 28% one-day drop. The ATTR-CM market is a genuine contest, with Pfizer's entrenched tafamidis (Vyndaqel/Vyndamax), BridgeBio's oral acoramidis (Attruby), and Ionis/AstraZeneca's eplontersen (Wainua) all competing, and new RNAi entrants keep raising capital. Biotech valuations are sensitive to clinical trial outcomes, and pipeline readouts in Alzheimer's and other areas could disappoint. Even after the slide, the stock trades near 40 times trailing earnings, which assumes years of strong growth. Drug pricing pressure, including government price negotiation under the Inflation Reduction Act, and patent or regulatory changes are ongoing overhangs. Debt of about $3.0 billion sits roughly level with the cash balance.
What is the Alnylam Pharmaceuticals, Inc. (ALNY) forecast?
27 analysts publish price targets on ALNY, averaging $299.96 as of November 2026, or +87.8% against the $159.73 share price on November 16, 2026. The published targets run from $180.00 to $455.00, a wide spread, and the ratings split 21 buy, 9 hold, 0 sell. Over the last six months there have been 0 raises and 12 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full ALNY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is ALNY a buy or a sell?
We give no verdict on Alnylam Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Amvuttra ATTR-CM ramp. The March 2025 approval of Amvuttra for ATTR cardiomyopathy opened a market many multiples larger than its original polyneuropathy indication, and the launch remains the single biggest growth driver: Amvuttra revenue rose 106% to about $1.01 billion in Q2 2026. The most optimistic published target, $455.00, assumes this works close to its best case.
The case against. Revenue is heavily concentrated in the TTR franchise, and the July 2026 guidance cut showed how sensitive the stock is to even a modest change in Amvuttra's trajectory: a roughly 4% trim to the total revenue range produced a 28% one-day drop. The most pessimistic target, $180.00, is roughly what ALNY is worth if this bites instead.
Read the full bull and bear case on ALNY, including what would have to change to break either one. Walnut is not an investment adviser.
Has Alnylam Pharmaceuticals, Inc. (ALNY) split its stock?
No. Alnylam Pharmaceuticals, Inc. (ALNY) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Alnylam Pharmaceuticals, Inc. (ALNY) valued?
Market cap, P/E and dividend yield at today's price are in the ALNY key stats above. The business figures below come from Alnylam Pharmaceuticals, Inc.'s reported results as of October 2026 and change when it next reports.
- Total revenue (TTM): ~$4.8B
- Net product revenue growth (Q2 2026 YoY): ~74% (to ~$1.17B)
- Amvuttra revenue (Q2 2026): ~$1.01B, up ~106%
- 2026 net product revenue guidance: ~$4.7B to $5.1B (cut from $4.9B to $5.3B)
- Net income (TTM): ~$775M (operating margin ~18%)
- Dividend: None
As of October 2026: After a 41% decline in 2026, Alnylam trades at about 6.6 times trailing revenue, near 40 times trailing earnings and about 19 times forward earnings, a much lower multiple than when guidance was first set. Consensus still expects about $5.5 billion of total revenue in 2026 and about $6.9 billion in 2027, so the valuation now hinges on whether the Q3 report on October 29 shows Amvuttra growth steadying after the guidance cut. It pays no dividend and reinvests cash into its RNAi pipeline.
What themes does Alnylam Pharmaceuticals, Inc. (ALNY) fit?
These are the investment theses ALNY naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.
Who competes with Alnylam Pharmaceuticals, Inc. (ALNY)?
ATTR amyloidosis rivals
Pfizer's tafamidis (Vyndaqel, Vyndamax, Vynmac) held the ATTR-CM market alone for years and remains the incumbent. BridgeBio's oral acoramidis (Attruby) and Ionis/AstraZeneca's eplontersen (Wainua) are newer entrants competing directly for the same cardiomyopathy patients, making this Alnylam's most important competitive battleground.
RNAi and genetic-medicine peers
Ionis Pharmaceuticals and Arrowhead Pharmaceuticals develop RNA-targeting therapeutics across overlapping rare and metabolic diseases, competing for the same scientific talent, targets, and partnerships. These companies validate the RNAi and antisense approach but also chase similar pipelines, so success is measured relative to them.
Large-cap biopharma partners and rivals
Novartis markets Leqvio (inclisiran), the RNAi cholesterol drug Alnylam invented and now earns royalties on, illustrating both partnership upside and reliance on larger players. Broader large-cap biopharma companies compete for capital, deals, and the same cardiovascular and neurology markets Alnylam is expanding into.
What stocks are similar to Alnylam Pharmaceuticals, Inc. (ALNY)?
Other names that sit close to ALNY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Alnylam Pharmaceuticals, Inc. (ALNY)
There are three common ways to get ALNY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ALNY sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where ALNY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY is a rare biotech that has turned a decade of RNAi science into a genuinely profitable, multi-billion-dollar commercial franchise, but the 2026 guidance cut showed how much the stock leans on Amvuttra's growth rate in a competitive ATTR market.
More on Alnylam Pharmaceuticals, Inc. (ALNY)
Whether ALNY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALNY a buy or a sell?, and where the stock could go from here in the ALNY stock forecast.
For income investors, whether ALNY pays a dividend and how the payout looks is covered in does ALNY pay a dividend? And to weigh ALNY against a peer, read the full side-by-side comparisons: ALNY vs VRTX and ALNY vs REGN.
Wondering how ALNY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Alnylam Pharmaceuticals, Inc.
Ask Walnut's AI anything about ALNY and see how it fits what you own.
FAQ
What does Alnylam Pharmaceuticals do?
+
Alnylam develops and sells RNA interference (RNAi) therapeutics, medicines that silence disease-causing genes. Its main products treat TTR amyloidosis (Amvuttra and Onpattro), acute hepatic porphyria (Givlaari), and a rare kidney disorder (Oxlumo). It also earns royalties on Leqvio, an RNAi cholesterol drug sold by Novartis. The company pioneered turning the RNAi mechanism into a repeatable drug-development platform.
Why is Amvuttra so important to ALNY?
+
Amvuttra (vutrisiran) is Alnylam's largest revenue driver by a wide margin. Its March 2025 FDA approval for ATTR cardiomyopathy expanded it into a much bigger patient population than its original nerve-disease indication. That single approval is the main reason revenue nearly doubled and the company reached profitability. Because so much revenue rests on it, Amvuttra's performance largely defines the investment case. The July 2026 cut to TTR guidance, tied to slower second-line demand, showed how directly Amvuttra's growth rate moves the stock.
Is Alnylam profitable?
+
Yes. After years of heavy research spending, Alnylam reached both GAAP and non-GAAP profitability for full-year 2025 on roughly $3 billion of net product revenue. It stayed profitable in 2026, with net income of about $206 million in Q1 and about $164 million in Q2, for trailing twelve-month net income near $775 million. Q2 non-GAAP operating income was about $318 million.
Does ALNY pay a dividend?
+
No, Alnylam does not pay a dividend. Like most growth-stage biotechs, it reinvests its cash into research, clinical trials, and commercial expansion of its RNAi pipeline. Investors in ALNY are relying entirely on share-price appreciation rather than income. That reflects a company still prioritizing growth over returning capital.
Who competes with Alnylam in ATTR amyloidosis?
+
Amvuttra competes against Pfizer's tafamidis (Vyndaqel/Vyndamax), which long dominated the ATTR-CM market, plus newer entrants BridgeBio's oral acoramidis (Attruby) and Ionis/AstraZeneca's eplontersen (Wainua). This has turned a once single-drug market into a genuine multi-way contest. Alnylam's angle is its quarterly subcutaneous dosing versus daily oral pills. Competitive share dynamics are a key thing to watch.
What are the main risks with ALNY?
+
The biggest risk is concentration: a large share of revenue depends on the TTR franchise, and the July 2026 guidance cut sent the shares down about 28% in a day. Biotech stocks are also sensitive to clinical trial outcomes, and the shares still trade near 40 times trailing earnings. Drug-pricing pressure and regulatory or patent changes add further uncertainty. Any of these could drive sharp price swings.
Is ALNY a good investment?
+
That depends on your own goals, risk tolerance, and time horizon, and Walnut is not an investment adviser, so this is not a recommendation. ALNY is a profitable, fast-growing biotech with a proven platform, but it carries concentration risk, and the 2026 guidance cut showed how much of the valuation rests on Amvuttra. Some investors see the 41% decline as a reset in expectations, while others find the reliance on one franchise too risky. Doing your own research or consulting a licensed adviser is wise.
How can I invest in Alnylam stock?
+
ALNY trades on the Nasdaq, so you can buy shares through any standard brokerage account. Some investors prefer to hold it within a diversified basket alongside other biotech or healthcare names to reduce single-stock risk. With Walnut, you can track ALNY inside a thematic basket tied to a stated investment thesis and place trades through your connected broker. How much to allocate is a personal decision based on your overall portfolio.
Why did Alnylam cut its 2026 guidance?
+
On July 30, 2026, Alnylam lowered 2026 TTR net product revenue guidance to $4.2 billion to $4.5 billion from $4.4 billion to $4.7 billion, and total net product revenue guidance to $4.7 billion to $5.1 billion from $4.9 billion to $5.3 billion. It said second-line US demand for Amvuttra had moderated to a normalized level after early pent-up demand from patients on stabilizers.
How did Alnylam do in its latest quarter?
+
In Q2 2026, net product revenue rose 74% to about $1.17 billion and Amvuttra revenue rose 106% to about $1.01 billion, with net income of about $164 million. EPS of about $1.84 missed the roughly $2.14 consensus. Alnylam reports Q3 2026 results on October 29, 2026, with consensus near $2.26 EPS on about $1.43 billion of revenue.
How has ALNY stock performed in 2026?
+
As of the October 16, 2026 close near $236, ALNY was down about 41% year to date and about 51% over one year. The largest single move was a roughly 28% drop after the July 30 guidance cut, which took the shares to a 52-week low of $197.81; the 52-week high was $495.55.
Guides that feature ALNY
ALNY is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Alnylam Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.